Molecular imaging company Enlyton Ltd. is seeking a $3 million investment to get its cancer-detection technology into clinical studies.
The Columbus, Ohio-based company believes its targeting agent, an antibody called ATA-1, is better than the industry standard at marking cancerous tumors in medical imaging scans.